Does Leptin Cause Vascular Disease?
2002; Lippincott Williams & Wilkins; Volume: 106; Issue: 15 Linguagem: Inglês
10.1161/01.cir.0000036864.14101.1b
ISSN1524-4539
AutoresJohn P. Cooke, Roberta K. Oka,
Tópico(s)Adipose Tissue and Metabolism
ResumoHomeCirculationVol. 106, No. 15Does Leptin Cause Vascular Disease? Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBDoes Leptin Cause Vascular Disease? John P. Cooke, MD, PhD and Roberta K. Oka, RN, DNSc John P. CookeJohn P. Cooke Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, Calif (J.P.C.), and School of Nursing, University of California, Los Angeles (R.K.O.). and Roberta K. OkaRoberta K. Oka Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, Calif (J.P.C.), and School of Nursing, University of California, Los Angeles (R.K.O.). Originally published8 Oct 2002https://doi.org/10.1161/01.CIR.0000036864.14101.1BCirculation. 2002;106:1904–1905In the past two decades, there has been a 2- to 4-fold increase in childhood obesity in the United States. The current epidemic of childhood obesity in the United States can be expected to cause a surge in cardiovascular disease in this generation.1,2 Already, obesity-related illnesses account for nearly 300 000 deaths and about $100 billion in economic costs per year in the United States. Therefore, understanding the mechanisms by which obesity accelerates vascular disease has become ever more important.See p 1919Mechanisms of Obesity-Induced Cardiovascular DiseaseObesity is associated with hypercholesterolemia, which is in some cases due to elevated levels of low-density lipoprotein cholesterol. Obesity-associated dyslipidemia is often due to metabolic syndrome, which is characterized by hypertriglyceridemia, hyperinsulinemia, hypertension, and reduced high-density lipoprotein cholesterol.3 Each component of the metabolic syndrome may contribute to the increased risk of cardiovascular disease observed in obesity. In addition, plasma levels of C-reactive peptide (CRP) increase with fat mass and decline with weight loss.4 Recently, CRP has been demonstrated to directly impair endothelium-dependent vasodilation,5 and it is also known to be predictive of increased cardiovascular events in patients with other risk factors or with vascular disease.6Obesity is also known to reduce vascular compliance.7 An increase in vascular stiffness has long-term adverse effects on the cardiovascular system by increasing impedance to blood flow and thereby increasing cardiovascular work and contributing to the development of left ventricular hypertrophy. Traditional risk factors are associated with vascular stiffness, and vascular stiffness is associated with an increased risk of cardiovascular events.8Leptin and Vascular DiseaseAnother factor that may underlie the association of obesity with vascular stiffness and cardiovascular disease is leptin. Leptin is a circulating peptide hormone produced by adipose cells that regulates body weight by effects on food intake and metabolism.9 By acting on hypothalamic receptors, leptin increases energy expenditure by enhancing sympathetic nervous activity and lipolysis. Leptin deficiency and resistance to the effects of leptin are each associated with weight gain. Leptin resistance, which is associated with hyperleptinemia, is much more common than leptin deficiency in human obesity.10In addition to hypothalamic receptors, there are receptors for leptin on the endothelium11 and on vascular smooth muscle cells.12 Accordingly, leptin can exert receptor-mediated influence on vessel tone and growth. In cell culture, leptin stimulates vascular smooth muscle proliferation and migration.12 Vascular calcification is also accelerated by leptin in experimental models.13 Additionally, leptin induces oxidative stress in endothelial cells; this action triggers the transcription of oxidant-sensitive genes that participate in atherogenesis, including monocyte chemotactic protein.14 Furthermore, leptin increases sympathetic nervous activity, and chronic administration of leptin increases blood pressure in experimental models.15 Accordingly, it is possible that the high levels of leptin observed in obesity could contribute to its adverse effects on cardiovascular health.Leptin and Vascular ComplianceThis issue of Circulation features an intriguing study that comes from a group that has contributed much to our understanding of human vascular function and its alteration by risk factors. Singhal and colleagues16 studied vascular function of the brachial artery in a healthy group of adolescents that had a broad range of body mass indexes. Using high-resolution ultrasound and a wall-tracking system, they assessed flow-mediated vasodilation (the increase in brachial artery diameter with increases in blood flow) and vascular distension (the increase in brachial artery diameter that occurs with the systolic pulse wave). The former is a reflection of endothelium-mediated vasodilation, and the latter is a measure of vascular compliance. The salient finding of this study16 was that high leptin levels are predictive of poor vascular compliance in adolescents. This effect of leptin was independent of the traditional risk factors and metabolic abnormalities that are observed in obesity. In fact, in these healthy adolescents, leptin was a better predictor of vascular compliance than the traditional risk factors, as well as fasting insulin and CRP.Leptin and Endothelial FunctionCuriously, plasma leptin levels were not correlated with flow-mediated vasodilation (FMVD). The investigators (incorrectly) concluded that "… the effect of leptin on arterial distensibility was independent of the short-term availability of endothelial nitric oxide." 16 One must be cautious in drawing conclusions from observations of FMVD in the brachial artery. Although in healthy individuals, NO plays a major role in this phenomenon, FMVD is not a direct measurement of the activity of endothelial nitric oxide synthase. Indeed, several endogenous vasodilators may contribute to FMVD in conduit vessels. These include prostacyclin and endothelium-dependent hyperpolarizing factor.17 Moreover, when NO elaboration is suppressed because of genetic or metabolic abnormalities, these secondary factors may assume a primary role in FMVD, compensating for any reduction in NO synthesis.18 Thus, early in the disease process, FMVD may appear normal at a time that NO synthesis or bioactivity is reduced. Therefore, it is possible that the adolescents in this study with high leptin levels had impairment of the NO synthase pathway, which was masked by compensatory increase in the synthesis of endothelium-derived hyperpolarizing factor and/or prostacyclin. A lack of correlation with FMVD does not exclude a deleterious effect of leptin on the NOS pathway.Alternatively, it is possible that leptin has opposing effects on vascular smooth muscle and endothelial function. Leptin has been shown to increase NO release from endothelial cells in vitro.19 When infused into leptin-deficient ob/ob mice, leptin enhances endothelium-dependent vasodilation ex vivo. Leptin stimulates angiogenesis, an effect that is known to require NO synthesis.11 The release of leptin by adipocytes may cause a local NO-mediated vasodilation in fatty tissue that enhances lipid metabolism.20 The effect of leptin to acutely trigger NO-mediated vasodilation is reminiscent of the effects of insulin on vascular reactivity. Acutely, insulin infused into the brachial artery of humans causes an increase in forearm blood flow and vasodilation.21 However, it is important to note here that the acute effects of insulin (and leptin) may be quite different from long-term elevations of these hormones. Both insulin and leptin are known to increase oxidative stress in endothelial cells. The long-term consequences of oxidative stress may include reductions in NO bioactivity and/or synthesis and an increase in the expression of adhesion molecules and chemokines that mediate vascular inflammation and atherogenesis. Furthermore, the associated metabolic changes that occur in a setting of resistance to insulin and to leptin (eg, increased levels of plasma fatty acids) are also known to impair endothelial function.SummaryTo conclude, the study by Singhal and colleagues16 reveals that elevated levels of leptin (often observed in overweight individuals) are associated with increased vascular stiffness. To strengthen a causal link between leptin and vascular stiffness, it will be important to determine the mechanism by which leptin impairs vascular compliance and to determine if nutritional or pharmacological interventions to reduce leptin levels and/or reduce leptin resistance can improve vascular compliance in these individuals. Nevertheless, Singhal and colleagues have added to our understanding of the association between leptin and cardiovascular disease. Perhaps more importantly, the study represents yet another harbinger of the epidemic to come, as widespread childhood obesity gives rise to an unwelcome epidemic of cardiovascular disease in this generation.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to John P. Cooke, MD, PhD, Section of Vascular Medicine, Stanford University School of Medicine, Division of Cardiovascular Medicine, 300 Pasteur Dr, Falk CVRC, Stanford, CA 94305-5406. E-mail [email protected] References 1 Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002; 106: 143–160.LinkGoogle Scholar2 Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999; 282: 1530–1538.CrossrefMedlineGoogle Scholar3 Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002; 106: 286–288.LinkGoogle Scholar4 Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002; 105: 564–569.CrossrefMedlineGoogle Scholar5 Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106: 913–919.LinkGoogle Scholar6 Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001; 89: 763–771.CrossrefMedlineGoogle Scholar7 Tounian P, Aggoun Y, Dubern B, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet. 2001; 358: 1400–1404.CrossrefMedlineGoogle Scholar8 Cohn J. Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making. Am J Hypertens. 2001; 14 (8 Pt 2): 258S–263S.Google Scholar9 Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998; 395: 763–770.CrossrefMedlineGoogle Scholar10 Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995; 1: 1155–1161.CrossrefMedlineGoogle Scholar11 Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998; 281: 1683–1686.CrossrefMedlineGoogle Scholar12 Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci. 2001; 47: 141–150.MedlineGoogle Scholar13 Parhami F, Tintut Y, Ballard A, et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res. 2001; 88: 954–960.CrossrefMedlineGoogle Scholar14 Yamagishi SI, Edelstein D, Du XL, et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001; 276: 25096–25100.CrossrefMedlineGoogle Scholar15 Haynes WG, Morgan DA, Walsh SA, et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997; 100: 270–278.CrossrefMedlineGoogle Scholar16 Singhal A, Farooqi IS, Cole TJ, et al. The influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002; 106: 1919–1924.LinkGoogle Scholar17 Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997; 48: 489–509.CrossrefMedlineGoogle Scholar18 Brandes RP, Schmitz-Winnenthal FH, Feletou M, et al. An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci U S A. 2000; 97: 9747–9752.CrossrefMedlineGoogle Scholar19 Winters B, Mo Z, Brooks-Asplund E, et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice. J Appl Physiol. 2000; 89: 2382–2390.CrossrefMedlineGoogle Scholar20 Mastronardi CA, Yu WH, McCann SM. Resting and circadian release of nitric oxide is controlled by leptin in male rats. Proc Natl Acad Sci U S A. 2002; 99: 5721–5726.CrossrefMedlineGoogle Scholar21 Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994; 94: 2511–2515.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Lin X, Gao L, Tian S, Klausen C, Guo M, Gao Q, Liu M, Wang H, Wu D, Zhou C, Yang J, Meng Y, Liu Y, Xu G, Tan Y, Ullah K, Zhu Y, Fraser W, Sheng J, Leung P, Muglia L, Wu Y and Huang H (2021) Maternal high-fat-diet exposure is associated with elevated blood pressure and sustained increased leptin levels through epigenetic memory in offspring, Scientific Reports, 10.1038/s41598-020-79604-4, 11:1, Online publication date: 1-Dec-2021. Matsubayashi M, Sakaguchi Y, Sahara Y, Nanaura H, Kikuchi S, Asghari A, Bui L, Kobashigawa S, Nakanishi M, Nagata R, Matsui T, Kashino G, Hasegawa M, Takasawa S, Eriguchi M, Tsuruya K, Nagamori S, Sugie K, Nakagawa T, Takasato M, Umetani M and Mori E (2020) 27‐Hydroxycholesterol regulates human SLC22A12 gene expression through estrogen receptor action , The FASEB Journal, 10.1096/fj.202002077R, 35:1, Online publication date: 1-Jan-2021. Simental-Mendía L, Sánchez-García A, Linden-Torres E and Simental-Mendía M (2021) Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials, Diabetes Research and Clinical Practice, 10.1016/j.diabres.2021.108899, 177, (108899), Online publication date: 1-Jul-2021. Lim Y, Oh J, Park U, Huh M and Hwang S (2020) Anti-obesity Effects of Mulberry Leaf and Yacon Extract in Obese Rats, Biomedical Science Letters, 10.15616/BSL.2020.26.2.75, 26:2, (75-84), Online publication date: 30-Jun-2020. Schindler T, Valenta I and Dilsizian V (2019) PET Myocardial Perfusion Imaging Cardiac CT, PET & MR, 10.1002/9781118754467.ch4, (129-174) Leijnse J, de Heus R, de Jager W, Rodenburg W, Peeters L, Franx A and Eijkelkamp N (2018) First trimester placental vascularization and angiogenetic factors are associated with adverse pregnancy outcome, Pregnancy Hypertension, 10.1016/j.preghy.2018.04.008, 13, (87-94), Online publication date: 1-Jul-2018. Shi K, Qian J, Qi L, Mao D, Chen Y, Zhu Y and Guo X (2016)(2016) Atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators via the upregulation of NF-κB activation in HCAECs, Oncology Letters, 10.3892/ol.2016.4796, 12:2, (1438-1444), Online publication date: 1-Aug-2016. Metwalley K, Farghaly H and Sherief T (2015) Left ventricular dysfunction and subclinical atherosclerosis in children with classic congenital adrenal hyperplasia: a single-center study from upper Egypt, European Journal of Pediatrics, 10.1007/s00431-015-2634-1, 175:3, (405-412), Online publication date: 1-Mar-2016. Chien H, Peng S, Hua T, Kuo C, Juang J and Tang S (2015) 3-D imaging of islets in obesity: formation of the islet–duct complex and neurovascular remodeling in young hyperphagic mice, International Journal of Obesity, 10.1038/ijo.2015.224, 40:4, (685-697), Online publication date: 1-Apr-2016. Bashir S, Sharma Y, Elahi A and Khan F (2015) Macrophage polarization: the link between inflammation and related diseases, Inflammation Research, 10.1007/s00011-015-0874-1, 65:1, (1-11), Online publication date: 1-Jan-2016. Ekmen N, Helvaci A, Gunaldi M, Sasani H and Yildirmak S (2016) Leptin as an important link between obesity and cardiovascular risk factors in men with acute myocardial infarction, Indian Heart Journal, 10.1016/j.ihj.2015.07.032, 68:2, (132-137), Online publication date: 1-Mar-2016. Husain K (2015) Inflammation, oxidative stress and renin angiotensin system in atherosclerosis, World Journal of Biological Chemistry, 10.4331/wjbc.v6.i3.209, 6:3, (209), . Chai S, Sun F, Nie X and Wang J (2014) Leptin and coronary heart disease: A systematic review and meta-analysis, Atherosclerosis, 10.1016/j.atherosclerosis.2013.11.069, 233:1, (3-10), Online publication date: 1-Mar-2014. Bekhite M, Finkensieper A, Rebhan J, Huse S, Schultze-Mosgau S, Figulla H, Sauer H and Wartenberg M (2014) Hypoxia, Leptin, and Vascular Endothelial Growth Factor Stimulate Vascular Endothelial Cell Differentiation of Human Adipose Tissue-Derived Stem Cells, Stem Cells and Development, 10.1089/scd.2013.0268, 23:4, (333-351), Online publication date: 15-Feb-2014. Schindler T, Quercioli A, Valenta I, Ambrosio G, Wahl R and Dilsizian V (2014) Quantitative Assessment of Myocardial Blood Flow—Clinical and Research Applications, Seminars in Nuclear Medicine, 10.1053/j.semnuclmed.2014.04.002, 44:4, (274-293), Online publication date: 1-Jul-2014. (2013) Static and Dynamic Modeling for Anthropometry Computational Modeling for Anthropometry, 10.1201/b15763-3, (17-39), Online publication date: 18-Sep-2013. Gandhi H and Balaraman R (2013) Involvement of Adipocytokines in Pathogenesis of Insulin Resistance, Obesity, and Metabolic Syndrome Metabolic Syndrome and Neurological Disorders, 10.1002/9781118395318.ch18, (297-310) (2013) Mathematical and Computational Modeling for Engineering and Sport Computational Modeling for Anthropometry, 10.1201/b15763-8, (107-120), Online publication date: 18-Sep-2013. (2013) Theoretical and Physical Modeling of Human Movement Science Computational Modeling for Anthropometry, 10.1201/b15763-12, (181-196), Online publication date: 18-Sep-2013. Yilmaz B and Toruner F (2013) 277 Endothelium, 10.1201/b14907-9, (229-277), Online publication date: 5-Jun-2013. (2013) Anthropometric Characteristics of Sportswomen Computational Modeling for Anthropometry, 10.1201/b15763-9, (121-141), Online publication date: 18-Sep-2013. (2013) Regression Method in Engineering and Sport Computational Modeling for Anthropometry, 10.1201/b15763-10, (143-163), Online publication date: 18-Sep-2013. (2013) Practice Hints for Regulating Body Weight Computational Modeling for Anthropometry, 10.1201/b15763-16, (237-261), Online publication date: 18-Sep-2013. Leal V and Mafra D (2013) Adipokines in obesity, Clinica Chimica Acta, 10.1016/j.cca.2013.02.003, 419, (87-94), Online publication date: 1-Apr-2013. Priya T, Chowdhury M, Vasanth K, Vijayakumar T, Ilango K, Agrawal A and Dubey G (2013) Correlation of serum leptin and resistin levels with the metabolic risk factors of pre- and postmenopausal women in South India, BioMedicine, 10.1016/j.biomed.2013.05.002, 3:4, (167-173), Online publication date: 1-Dec-2013. (2013) Engineering and Sport Exercising Computational Modeling for Anthropometry, 10.1201/b15763-6, (65-83), Online publication date: 18-Sep-2013. (2013) Biomechanical Techniques and Human Movement Computational Modeling for Anthropometry, 10.1201/b15763-7, (85-105), Online publication date: 18-Sep-2013. Priya T, Chowdhury M, Vasanth K, Vijayakumar T, Ilango K, Agrawal A and Dubey G (2013) WITHDRAWN: Assessment of serum leptin and resistin levels in association with the metabolic risk factors of pre- and post-menopausal rural women in South India, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 10.1016/j.dsx.2013.06.016, 7:4, (233-237), Online publication date: 1-Oct-2013. Jung C (2013) Associations of Visceral Adipose Tissue and Adipokines with Incident Acute Myocardial Infarction, The Korean Journal of Obesity, 10.7570/kjo.2013.22.3.145, 22:3, (145), . Jeong H (2013) Efficacy of Alismatis Orientale Rhizoma on Obesity induced by High Fat Diet, The Korea Journal of Herbology, 10.6116/kjh.2013.28.3.95, 28:3, (95-106), Online publication date: 30-May-2013. Rajendran K, Devarajan N, Ganesan M and Ragunathan M (2012) Obesity, Inflammation and Acute Myocardial Infarction - Expression of leptin, IL-6 and high sensitivity-CRP in Chennai based population, Thrombosis Journal, 10.1186/1477-9560-10-13, 10:1, Online publication date: 1-Dec-2012. Lobato N, Neves K, Filgueira F, Fortes Z, Carvalho M, Webb R, Oliveira A and Tostes R (2012) The adipokine chemerin augments vascular reactivity to contractile stimuli via activation of the MEK-ERK1/2 pathway, Life Sciences, 10.1016/j.lfs.2012.04.013, 91:13-14, (600-606), Online publication date: 1-Oct-2012. Dozio E, Barassi A, Dogliotti G, Malavazos A, Colpi G, D'Eril G and Corsi M (2012) Adipokines, Hormonal Parameters, and Cardiovascular Risk Factors: Similarities and Differences Between Patients with Erectile Dysfunction of Arteriogenic and Nonarteriogenic Origin, The Journal of Sexual Medicine, 10.1111/j.1743-6109.2012.02781.x, 9:9, (2370-2377), Online publication date: 1-Sep-2012. Tesauro M, Canale M, Rodia G, Di Daniele N, Lauro D, Scuteri A and Cardillo C (2011) Metabolic Syndrome, Chronic Kidney, and Cardiovascular Diseases: Role of Adipokines, Cardiology Research and Practice, 10.4061/2011/653182, 2011, (1-11), . Sun Y, Li J, Luan Y and Wang L (2010) Effect of statin therapy on leptin levels in patients with coronary heart disease, Peptides, 10.1016/j.peptides.2010.03.023, 31:6, (1205-1207), Online publication date: 1-Jun-2010. Singh M, Bedi U, Singh P, Arora R and Khosla S (2010) Leptin and the clinical cardiovascular risk, International Journal of Cardiology, 10.1016/j.ijcard.2009.07.019, 140:3, (266-271), Online publication date: 1-Apr-2010. Karatela R and Sainani G (2010) Interrelationships of factor VII activity and plasma leptin with insulin resistance in coronary heart disease, Atherosclerosis, 10.1016/j.atherosclerosis.2009.08.043, 209:1, (235-240), Online publication date: 1-Mar-2010. Fagerer N and Kullich W (2010) Adipozytokine bei Rheumatoider Arthritis und AdipositasAdipocytokines in rheumatoid arthritis and obesity, Wiener Medizinische Wochenschrift, 10.1007/s10354-010-0808-z, 160:15-16, (391-398), Online publication date: 1-Aug-2010. Söderberg S, Colquhoun D, Keech A, Yallop J, Barnes E, Pollicino C, Simes J, Tonkin A and Nestel P (2008) Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study, International Journal of Obesity, 10.1038/ijo.2008.224, 33:1, (123-130), Online publication date: 1-Jan-2009. Varady K, Tussing L, Bhutani S and Braunschweig C (2009) Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women, Metabolism, 10.1016/j.metabol.2009.04.010, 58:8, (1096-1101), Online publication date: 1-Aug-2009. Sainani G and Karatela R (2009) Plasma Leptin in Insulin-Resistant and Insulin-Nonresistant Coronary Artery Disease and Its Association With Cardio-Metabolic Risk Factors Among Asian Indians, Metabolic Syndrome and Related Disorders, 10.1089/met.2008.0097, 7:4, (335-340), Online publication date: 1-Aug-2009. Quan M (2009) Introduction, Clinical Cornerstone, 10.1016/S1098-3597(09)80001-X, 9:4, (7-8), Online publication date: 1-Jan-2009. Bray G, Clearfield M, Fintel D and Nelinson D (2009) Overweight and obesity: The pathogenesis of cardiometabolic risk, Clinical Cornerstone, 10.1016/S1098-3597(09)80003-3, 9:4, (30-42), Online publication date: 1-Jan-2009. Aronne L, Nelinson D and Lillo J (2009) Obesity as a disease state: A new paradigm for diagnosis and treatment, Clinical Cornerstone, 10.1016/S1098-3597(09)80002-1, 9:4, (9-29), Online publication date: 1-Jan-2009. Kim S, Bae Y, Bae S, Choi K, Yoon K, Koo T, Jang H, Yun I, Kim K, Kwon Y, Yoo M and Bae M (2008) Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-κB activation in endothelial cells, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 10.1016/j.bbamcr.2008.01.004, 1783:5, (886-895), Online publication date: 1-May-2008. Galluccio E, Piatti P, Citterio L, Lucotti P, Setola E, Cassina L, Oldani M, Zavaroni I, Bosi E, Colombo A, Alfieri O, Casari G, Reaven G and Monti L (2008) Hyperinsulinemia and impaired leptin-adiponectin ratio associate with endothelial nitric oxide synthase polymorphisms in subjects with in-stent restenosis, American Journal of Physiology-Endocrinology and Metabolism, 10.1152/ajpendo.00003.2008, 294:5, (E978-E986), Online publication date: 1-May-2008. Karuparthi P, Yerram P, Govindarajan G and Hayden M (2008) Obesity and cardiovascular risk, Current Cardiovascular Risk Reports, 10.1007/s12170-008-0022-3, 2:2, (113-119), Online publication date: 1-Mar-2008. Rahmani-nia F, Rahnama N, Hojjati Z and Soltani B (2008) Acute effects of aerobic and resistance exercises on serum leptin and risk factors for coronary heart disease in obese females, Sport Sciences for Health, 10.1007/s11332-008-0050-x, 2:3, (118-124), Online publication date: 1-Mar-2008. Antuna-Puente B, Feve B, Fellahi S and Bastard J (2008) Adipokines: The missing link between insulin resistance and obesity, Diabetes & Metabolism, 10.1016/j.diabet.2007.09.004, 34:1, (2-11), Online publication date: 1-Feb-2008. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami A, Sert Kuniyoshi F, Wolk R and Somers V (2007) Relation of Increased Leptin Concentrations to History of Myocardial Infarction and Stroke in the United States Population††All the analysis, interpretation, and/or conclusion reached in this study are the work of the authors and not of the National Center for Health Statistics, Hyattsville, Maryland., The American Journal of Cardiology, 10.1016/j.amjcard.2007.02.088, 100:2, (234-239), Online publication date: 1-Jul-2007. Antuna-Puente B, Feve B, Fellahi S and Bastard J (2007) Obésité, inflammation et insulinorésistance : quel rôle pour les adipokines ?, Therapies, 10.2515/therapie:2007055, 62:4, (285-292), Online publication date: 1-Jul-2007. Şahin A and Bariskaner H (2007) The mechanisms of vasorelaxant effect of leptin on isolated rabbit aorta, Fundamental & Clinical Pharmacology, 10.1111/j.1472-8206.2007.00541.x, 21:6, (595-600), Online publication date: 1-Dec-2007. Karuparthi P, Yerram P, Saab G, McFarlane S and Whaley-Connell A (2007) Obesity and chronic kidney disease: therapeutic implications, Therapy, 10.2217/14750708.4.5.585, 4:5, (585-595), Online publication date: 1-Sep-2007. Li Z, Li F, Yan L, Li F, Li Y, Cheng H and Fu Z (2007) Study on the action of resistin-induced human umbilical vein endothelial cell dysfunction, Frontiers of Medicine in China, 10.1007/s11684-007-0037-z, 1:2, (196-199), Online publication date: 1-May-2007. Lolmède K, Curat C, Bouloumié A, Miranville A and Sengenès C (2007) Leptin as a Vasoactive Adipokine Obesity, 10.1201/9781420005479.ch8, (93-103), Online publication date: 7-Mar-2007. Schindler T, Cardenas J, Prior J, Facta A, Kreissl M, Zhang X, Sayre J, Dahlbom M, Licinio J and Schelbert H (2006) Relationship Between Increasing Body Weight, Insulin Resistance, Inflammation, Adipocytokine Leptin, and Coronary Circulatory Function, Journal of the American College of Cardiology, 10.1016/j.jacc.2005.10.062, 47:6, (1188-1195), Online publication date: 1-Mar-2006. Wu Z, Zhao S and Ye H (2006) The beneficial effects of high-density lipoprotein on adipocytes may relate to its anti-atherogenic properties, Medical Hypotheses, 10.1016/j.mehy.2006.03.052, 67:5, (1195-1199), . Brahmkshatriya P, Jani M and Chhabria M (2008) Recent developments in the treatment of atherosclerosis, Journal of Enzyme Inhibition and Medicinal Chemistry, 10.1080/14756360500337634, 21:1, (1-15), Online publication date: 1-Jan-2006. Zschenker O, Illies T and Ameis D (2006) Overexpression of Lysosomal Acid Lipase and Other Proteins in Atherosclerosis, The Journal of Biochemistry, 10.1093/jb/mvj137, 140:1, (23-38), Online publication date: 1-Jul-2006. Baráth Á, Túri S, Németh I, Bereczki C, Gellén B, Haszon I and Monostori P (2006) Different pathomechanisms of essential and obesity-associated hypertension in adolescents, Pediatric Nephrology, 10.1007/s00467-006-0215-2, 21:10, (1419-1425), Online publication date: 1-Oct-2006. Kumagai S, Kishimoto H, Masatakasuwa , Zou B and Harukasasaki (2005) The Leptin to Adiponectin Ratio Is a Good Biomarker for the Prevalence of Metabolic Syndrome, Dependent on Visceral Fat Accumulation and Endurance Fitness in Obese Patients with Diabetes Mellitus, Metabolic Syndrome and Related Disorders, 10.1089/met.2005.3.85, 3:2, (85-94), Online publication date: 1-Jun-2005. Skilton M, Nakhla S, Sieveking D, Caterson I and Celermajer D (2005) Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells, Clinical and Experimental Pharmacology and Physiology, 10.1111/j.1440-1681.2005.04274.x, 32:10, (839-844), Online publication date: 1-Oct-2005. GIANDOMENICO G, DELLAS C, CZEKAY R, KOSCHNICK S and LOSKUTOFF D (2005) The leptin receptor system of human platelets, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2005.01327.x, 3:5, (1042-1049), Online publication date: 1-May-2005. Piñeiro R, J M, Eiras S, Viñuela J, Lago F and González-Juanatey J (2009) Leptin does not Induce Hypertrophy, Cell Cycle Alterations, or Production of MCP-1 in Cultured Rat and Mouse Cardiomyocytes, Endocrine Research, 10.1080/07435800500456937, 31:4, (375-386), Online publication date: 1-Jan-2005. KOFLER S, NICKEL T and WEIS M (2005) Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation, Clinical Science, 10.1042/CS20040174, 108:3, (205-213), Online publication date: 1-Mar-2005. Kampf C, Bodin B, Källskog O, Carlsson C and Jansson L (2005) Marked Increase in White Adipose Tissue Blood Perfusion in the Type 2 Diabetic GK Rat, Diabetes, 10.2337/diabetes.54.9.2620, 54:9, (2620-2627), Online publication date: 1-Sep-2005. Kusminski C, Mcternan P and Kumar S (2005) Role of resistin in obesity, insulin resistance and Type II diabetes, Clinical Science, 10.1042/CS20050078, 109:3, (243-256), Online publication date: 1-Sep-2005. Lau D, Dhillon B, Yan H, Szmitko P and Verma S (2005) Adipokines: molecular links between obesity and atheroslcerosis, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.01058.2004, 288:5, (H2031-H2041), Online publication date: 1-May-2005. Konstantinides S, Schäfer K, Neels J, Dellas C and Loskutoff D (2004) Inhibition of Endogenous Leptin Protects Mice From Arterial and Venous Thrombosis, Arteriosclerosis, Thrombosis, and Vascular Biology, 24:11, (2196-2201), Online publication date: 1-Nov-2004. Porreca E, Febbo C, Moretta V, Angelini A, Guglielmi M, Nisio M and Cuccurullo F (2004) Circulating leptin is associated with oxidized LDL in postmenopausal women, Atherosclerosis, 10.1016/j.atherosclerosis.2004.03.010, 175:1, (139-143), Online publication date: 1-Jul-2004. Soderberg S, Stegmayr B, Stenlund H, Sjostrom L, Agren A, Johansson L, Weinehall L and Olsson T (2004) Leptin, but not adiponectin, predicts stroke in males, Journal of Internal Medicine, 10.1111/j.1365-2796.2004.01351.x, 256:2, (128-136), Online publication date: 1-Aug-2004. Verma S, Li S, Wang C, Fedak P, Li R, Weisel R and Mickle D (2003) Resistin Promotes Endothelial Cell Activation, Circulation, 108:6, (736-740), Online publication date: 12-Aug-2003.Piatti P, Di Mario C, Monti L, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A and Colombo A (2003) Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting, Circulation, 108:17, (2074-2081), Online publication date: 28-Oct-2003. Keller K and Lemberg L (2003) Obesity and the Metabolic Syndrome, American Journal of Critical Care, 10.4037/ajcc2003.12.2.167, 12:2, (167-170), Online publication date: 1-Mar-2003. Para I, Albu A and Porojan M (2021) Adipokines and Arterial Stiffness in Obesity, Medicina, 10.3390/medicina57070653, 57:7, (653) Danilov N, Gorgadze T, Savchenko A and Chazova I (2006) Restenoz posle koronarnogo stentirovaniya u bol'nykh s metabolicheskim sindromom, Systemic Hypertension, 10.26442/SG28761, 3:1, (47-50) Annweiler C, Duval G, Cheng C, Wong T, Lamoureux E, Milea D and Sabanayagam C (2019) U-Shaped Relationship between Serum Leptin Concentration and Cognitive Performance in Older Asian Adults, Nutrients, 10.3390/nu11030660, 11:3, (660) October 8, 2002Vol 106, Issue 15 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000036864.14101.1BPMID: 12370209 Originally publishedOctober 8, 2002 Keywordslipidscardiovascular diseasesvasodilationEditorialshormonesPDF download Advertisement
Referência(s)